Vertex Pharmaceuticals Incorporated (VRTX) Q2 2009 Earnings Results

Vertex Pharmaceuticals Misses on Revenue, Stock Down 2.12%

Vertex Pharmaceuticals reported a loss per share of $0.75, which was slightly better than expected. However, the lack of revenue figures and no guidance update contributed to a stock decline of 2.12%. Investors may be concerned about the company's future performance without clearer financial direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.75	N/A	+6.60%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record for this earnings call, so the analysis is based solely on the numerical results.

Vertex Pharmaceuticals Misses on Revenue, Stock Down 2.12%

Key numbers

Management commentary

Vertex Pharmaceuticals Incorporated

More earnings this week

Vertex Pharmaceuticals Misses on Revenue, Stock Down 2.12%

Key numbers

Management commentary